利拉鲁肽治疗2型糖尿病：临床数据及使用中的实际考量

Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use.

作者信息

Ampudia-Blasco Francisco Javier, Gómez Carlos Calvo, Claramunt Xavier Cos, Alegría Javier García, Gimeno Esteban Jódar, Bravo José Javier Mediavilla, Raya Pedro Mezquita, Pérez Jorge Navarro, Domingo Manel Puig

机构信息

a Diabetes Reference Unit, Clinical University Hospital, Valencia, Spain.

b Hypertension and Vascular Risk Unit, Internal Medicine Department, Santiago de Compostela University Hospital Complex, A Coruña, Spain.

出版信息

Expert Rev Endocrinol Metab. 2010 Nov;5(6):799-807. doi: 10.1586/eem.10.59.

DOI:10.1586/eem.10.59

PMID:30780828

Abstract

Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinical practice. It has recently been approved by the EMA and the US FDA for treatment of Type 2 diabetes mellitus (T2DM). Initial approval is for use in combination with either metformin or a sulfonylurea, or in combination with metformin plus a sulfonylurea or thiazolidinedione. Liraglutide monotherapy is approved in the USA. Results from the Liraglutide Effect and Action in Diabetes (LEAD) clinical trials program indicate that liraglutide significantly lowers glycosylated hemoglobin (HbA) with a low risk of hypoglycemia. Liraglutide is also associated with significant and sustained weight loss, decreased systolic blood pressure, and improvements in other markers of cardiovascular risk. Liraglutide also shows strong potential to preserve β-cell function. Maximum benefits may be achieved when liraglutide treatment is initiated early on in the course of T2DM.

摘要

利拉鲁肽是首个可用于临床实践的每日一次注射的人胰高血糖素样肽-1类似物。它最近已获得欧洲药品管理局（EMA）和美国食品药品监督管理局（US FDA）批准，用于治疗2型糖尿病（T2DM）。最初批准的用法是与二甲双胍或磺脲类药物联合使用，或与二甲双胍加磺脲类药物或噻唑烷二酮联合使用。在美国，利拉鲁肽单药治疗已获批准。利拉鲁肽在糖尿病中的作用和疗效（LEAD）临床试验项目的结果表明，利拉鲁肽能显著降低糖化血红蛋白（HbA），且低血糖风险较低。利拉鲁肽还与显著且持续的体重减轻、收缩压降低以及心血管风险的其他指标改善有关。利拉鲁肽在保护β细胞功能方面也显示出强大潜力。在2型糖尿病病程早期开始使用利拉鲁肽治疗时，可能会获得最大益处。